--- title: "RSV vaccination: a cost-effective strategy for older adults in the Netherlands" description: RSV vaccination for older adults in the Netherlands is cost-effective, preventing thousands of GP visits and hospitalizations while saving millions in healthcare costs. image: https://health-ecore.com/hubfs/AI-Generated%20Media/Images/RSV%20virus%20colourfull%20healthecore%20colours%20pink%20green%20blue-1.png --- [Skip to the main content.](https://health-ecore.com/news/rsv-vaccination-a-cost-effective-strategy-for-older-adults-in-the-netherlands#main-content) [![HE\_logo\_fc-35-1](https://health-ecore.com/hs-fs/hubfs/HE_logo_fc-35-1.png?width=1500&height=326&name=HE_logo_fc-35-1.png "HE_logo_fc-35-1")](https://health-ecore.com/) [![Health-Ecore](https://health-ecore.com/hs-fs/hubfs/HE_logo_fc-35.png?width=1772&height=385&name=HE_logo_fc-35.png "Health-Ecore")](https://health-ecore.com/) - [Home](https://health-ecore.com) - [About us](https://health-ecore.com/about-us) - Our work - [Scientific work](https://health-ecore.com/publications) - [RSV web app](https://health-ecore.com/news/rsv-vaccination-a-cost-effective-strategy-for-older-adults-in-the-netherlands) - [DRAIGON SLR app](https://slrmadraigon.apps.health-ecore.com/) - [Team](https://health-ecore.com/team) - [News](https://health-ecore.com/news) - [Contact](https://health-ecore.com/contact) Toggle Menu Toggle Menu - [Home](https://health-ecore.com) - [About us](https://health-ecore.com/about-us) - Our work - [Scientific work](https://health-ecore.com/publications) - [RSV web app](https://health-ecore.com/news/rsv-vaccination-a-cost-effective-strategy-for-older-adults-in-the-netherlands) - [DRAIGON SLR app](https://slrmadraigon.apps.health-ecore.com/) - [Team](https://health-ecore.com/team) - [News](https://health-ecore.com/news) - [Contact](https://health-ecore.com/contact) [Linkedin](https://www.linkedin.com/company/health-ecore/posts/?feedView=all) 1 min read # RSV vaccination: a cost-effective strategy for older adults in the Netherlands [![Picture of Florian Zeevat](https://app.hubspot.com/settings/avatar/73887c1c8e359a90139f5bcfb08aae22) Florian Zeevat](https://health-ecore.com/news/author/florian-zeevat) : Published October 2, 2025 [Public Health](https://health-ecore.com/news/tag/public-health) [Infectious Disease](https://health-ecore.com/news/tag/infectious-disease) [RSV](https://health-ecore.com/news/tag/rsv) [Vaccination](https://health-ecore.com/news/tag/vaccination) ![RSV vaccination: a cost-effective strategy for older adults in the Netherlands](https://health-ecore.com/hs-fs/hubfs/AI-Generated%20Media/Images/RSV%20virus%20colourfull%20healthecore%20colours%20pink%20green%20blue-1.png?width=1536&height=805&name=RSV%20virus%20colourfull%20healthecore%20colours%20pink%20green%20blue-1.png) Respiratory Syncytial Virus (RSV) is increasingly recognized as a serious health threat for older adults. In the Netherlands, RSV may lead to thousands of GP visits and hospitalizations annually among adults aged 60 and older, but the extent of this burden remains uncertain and is probably underreported.  In March 2025, the Dutch Health Council recommended offering RSV vaccination to adults aged 75 and older, as well as those aged 60–74 living in long-term care or with medical risk conditions. While the vaccines are considered safe and effective, questions remain about the duration of protection and the potential need for booster doses. To support policy decisions, Health-Ecore developed an independent cost-effectiveness model evaluating various vaccination strategies in the Netherlands. The model integrates real-world effectiveness data on hospitalization with meta-analysis-based efficacy estimates for outpatient and non-medically attended cases. It assesses multiple strategies, including triennial and biennial vaccination intervals, across different older age groups.   ![Afbeelding4](https://health-ecore.com/hs-fs/hubfs/Afbeelding4.jpg?width=3497&height=1028&name=Afbeelding4.jpg)   Key Findings  The results show that triennial vaccination of adults aged ≥75 and high-risk individuals aged 60–74 could have a significant public health and economic impact. In the first year alone, this strategy could prevent:  - **19,000 GP visits** - **3,300 hospitalizations**, including **245 ICU admissions** - **870 deaths** - Save **€29.5 million in healthcare costs** and **€6.3 million in productivity losses** - Gain **2,900 quality-adjusted life years (QALYs)** This strategy is cost-effective, with an average cost-effectiveness ratio (ACER) of **€30,804 per QALY** gained  Among all strategies evaluated, vaccinating adults aged ≥75 every three years was the most cost-effective, with an incremental cost-effectiveness ratio (ICER) of **€23,080 per QALY** compared to no vaccination. While vaccinating all adults aged ≥60 resulted in the highest QALY gain, it came at a higher cost (ICER: **€107,623 per QALY** compared to the ≥75 and high-risk strategy). Biennial strategies were less favorable and dominated in incremental comparisons.  ![Afbeelding6](https://health-ecore.com/hs-fs/hubfs/Afbeelding6.jpg?width=1061&height=446&name=Afbeelding6.jpg)   Want to gain more insights? Read the full article or explore the model results in the interactive online model, built using R. [Read the paper](https://doi.org/10.1016/j.vaccine.2025.127735) [Interactive model](https://health-ecore.shinyapps.io/rsv_model/)     This research is based on an open and independent model that evaluates a generic RSV vaccine to support national decision-making. The study was conducted in collaboration with Moderna and Pfizer.    [![RSV immunization for children](https://health-ecore.com/hubfs/Blog%20images/cdc-oGJQt3-X_FY-unsplash-1-1.jpeg)](https://health-ecore.com/news/en/news/rsv-immunization-for-children) #### [RSV immunization for children](https://health-ecore.com/news/en/news/rsv-immunization-for-children) [![Picture of Simon van der Pol](https://app.hubspot.com/settings/avatar/6076bb0cafb0b64e016c0b629cc901de) Simon van der Pol](https://health-ecore.com/news/author/simon-van-der-pol) : 21 May 2025, 00:00:00 CEST Discover how nirsevimab offers cost-effective RSV prevention for Dutch infants, supporting universal immunization and reducing healthcare costs. [Public Health](https://health-ecore.com/news/tag/public-health) [Infectious Disease](https://health-ecore.com/news/tag/infectious-disease) [RSV](https://health-ecore.com/news/tag/rsv) [Read More](https://health-ecore.com/news/en/news/rsv-immunization-for-children) [![Launch of the vaccination guideline for adults with chronic lung disease](https://health-ecore.com/hubfs/Blog%20images/ChrisBonis_34A9231-lowres-online.jpeg)](https://health-ecore.com/news/launch-of-the-vaccination-guideline-for-adults-with-chronic-lung-disease) #### [Launch of the vaccination guideline for adults with chronic lung disease](https://health-ecore.com/news/launch-of-the-vaccination-guideline-for-adults-with-chronic-lung-disease) [![Picture of Simon van der Pol](https://app.hubspot.com/settings/avatar/6076bb0cafb0b64e016c0b629cc901de) Simon van der Pol](https://health-ecore.com/news/author/simon-van-der-pol) : 25 September 2025, 13:25:48 CEST New national guideline launched to improve vaccination for adults with chronic lung disease, providing clear recommendations to enhance prevention... [Public Health](https://health-ecore.com/news/tag/public-health) [Infectious Disease](https://health-ecore.com/news/tag/infectious-disease) [RSV](https://health-ecore.com/news/tag/rsv) [Chronic Lung Diseases](https://health-ecore.com/news/tag/chronic-lung-diseases) [Vaccination](https://health-ecore.com/news/tag/vaccination) [Pneumococcal](https://health-ecore.com/news/tag/pneumococcal) [COVID-19](https://health-ecore.com/news/tag/covid-19) [Influenza](https://health-ecore.com/news/tag/influenza) [Read More](https://health-ecore.com/news/launch-of-the-vaccination-guideline-for-adults-with-chronic-lung-disease) [![The Value of Efforts to Increase Vaccination Uptake in the Netherlands](https://health-ecore.com/hubfs/istockphoto-1668066413-612x612.jpeg)](https://health-ecore.com/news/the-societal-value-of-higher-vaccination-rates-in-the-netherlands) #### [The Value of Efforts to Increase Vaccination Uptake in the Netherlands](https://health-ecore.com/news/the-societal-value-of-higher-vaccination-rates-in-the-netherlands) [Ece Aydin](https://health-ecore.com/news/author/ece-aydin) : 7 May 2026, 14:09:40 CEST The economic case for higher vaccination uptake in the Netherlands, what each percentage point gain is worth to society across measles, pertussis,... [Public Health](https://health-ecore.com/news/tag/public-health) [Infectious Disease](https://health-ecore.com/news/tag/infectious-disease) [Vaccination](https://health-ecore.com/news/tag/vaccination) [Health Policy](https://health-ecore.com/news/tag/health-policy) [Read More](https://health-ecore.com/news/the-societal-value-of-higher-vaccination-rates-in-the-netherlands) [![Adjuvanted influenza vaccine is a cost-effective investment for older adults in the Netherlands](https://health-ecore.com/hubfs/Realistic%20Elderly%20Couple%20at%20GP%20Office%20Vaccination%20Consultation-1-1.png)](https://health-ecore.com/news/evaluating-the-cost-effectiveness-of-adjuvanted-influenza-vaccine-in-the-older-adult-population-in-the-netherlands) #### [Adjuvanted influenza vaccine is a cost-effective investment for older adults in the Netherlands](https://health-ecore.com/news/evaluating-the-cost-effectiveness-of-adjuvanted-influenza-vaccine-in-the-older-adult-population-in-the-netherlands) [Susan de Braak](https://health-ecore.com/news/author/susan-de-braak) : 3 July 2026, 11:55:01 CEST Adjuvanted influenza vaccines for older adults in the Netherlands are a cost-effective strategy, reducing hospitalizations and healthcare costs... [Vaccination](https://health-ecore.com/news/tag/vaccination) [Influenza](https://health-ecore.com/news/tag/influenza) [Cost-effectiveness analysis](https://health-ecore.com/news/tag/cost-effectiveness-analysis) [Read More](https://health-ecore.com/news/evaluating-the-cost-effectiveness-of-adjuvanted-influenza-vaccine-in-the-older-adult-population-in-the-netherlands) ![HE\_Invest\_Innovate\_Implement-39](https://health-ecore.com/hs-fs/hubfs/HE_Invest_Innovate_Implement-39.png?width=500&height=36&name=HE_Invest_Innovate_Implement-39.png)   - [Contact details](https://health-ecore.com/contact) - [Privacy policy](https://health-ecore.com/privacy-policy) - [LinkedIn policy](https://health-ecore.com/linkedin-rules) © 2026 Health-Ecore B.V. [Linkedin](https://www.linkedin.com/company/health-ecore/posts/?feedView=all) [GitHub](https://github.com/Health-Ecore) Chamber of Commerce: 72059419 | Tax registration: NL 858968447 B01 Return to top ```json { "@context" : "https://schema.org", "@type" : "BlogPosting", "author" : { "@type" : "Person", "name" : "Florian Zeevat", "url" : "https://health-ecore.com/news/author/florian-zeevat" }, "dateModified" : "2025-10-02T07:30:01.028Z", "datePublished" : "2025-10-02T07:30:01.000Z", "headline" : "RSV vaccination: a cost-effective strategy for older adults in the Netherlands", "image" : [ "https://health-ecore.com/hubfs/AI-Generated%20Media/Images/RSV%20virus%20colourfull%20healthecore%20colours%20pink%20green%20blue-1.png" ], "mainEntityOfPage" : { "@id" : "https://health-ecore.com/news/rsv-vaccination-a-cost-effective-strategy-for-older-adults-in-the-netherlands", "@type" : "WebPage" }, "publisher" : { "@type" : "Organization", "logo" : { "@type" : "ImageObject", "url" : "https://health-ecore.com/hubfs/HE_logo_fc-35.png" }, "name" : "Health-Ecore B.V." } } ``` ```json { "@context" : "https://schema.org", "@type" : "BlogPosting", "author" : [ { "@type" : "Person", "name" : "Florian Zeevat", "url" : "https://health-ecore.com/news/author/florian-zeevat" } ], "dateModified" : "2025-10-02T07:30:01Z", "datePublished" : "2025-10-02T07:30:01Z", "description" : "RSV vaccination for older adults in the Netherlands is cost-effective, preventing thousands of GP visits and hospitalizations while saving millions in healthcare costs.", "headline" : "RSV vaccination: a cost-effective strategy for older adults in the Netherlands", "image" : [ "https://26748615.fs1.hubspotusercontent-eu1.net/hubfs/26748615/AI-Generated%20Media/Images/RSV%20virus%20colourfull%20healthecore%20colours%20pink%20green%20blue-1.png" ], "inLanguage" : "en", "keywords" : "Public Health, Infectious Disease, RSV, Vaccination", "mainEntityOfPage" : { "@id" : "https://health-ecore.com/news/rsv-vaccination-a-cost-effective-strategy-for-older-adults-in-the-netherlands", "@type" : "WebPage" }, "publisher" : { "@type" : "Organization", "name" : "Health-Ecore B.V." } } ```